Galenix, a pharmaceutical drug delivery and drug product development company from France, will soon set up base in India.

The company is on the look out for Joint Ventures or acquisition as an opportunity to conduct R&D activities in India.

Galenix, has 3 business units in accordance to European GMP and US FDA standards. While Galenix Pharma is involved in manufacturing, Galenix Développement focuses on R&D and delivery Systems. The Galenix Innovations carries out technology surveys, innovative formulation design and feasibility studies for patented technologies.

"We are looking for a JV or acquisition to do business in India, where we could present our own Galenix technologies and produce with Indian expertise in a low cost," Jerome Basse, CEO and chairman, Galenix Developpement, Saing Jean D'illac, France told Pharmabiz. The company is on the look out of dedicated R&D set ups, ideally with staff strength of 70 people.

He said that India has emerged as a secure territory for research and manufacturing of patented products with the new IPR norms, and the company would leverage the availability of competitive expertise at cheap cost. The company is planning to make its presence in India before the end of 2008.

"If we are not able to complete an Indian acquisition by mid 2007, we will set up our own facilities in India," explained Basse. The facilities would be aimed to work for firms from the European countries and US market. The company has also developed technologies for pharmaceutical processes, which it would implicate in the operations in India later.